Immediate Impact
3 from Science/Nature 52 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
Works of C. Lund being referenced
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial
2022
Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| C. Lund | 114 | 106 | 133 | 160 | 20 | 382 | |
| Katrin Håkansson | 93 | 146 | 131 | 189 | 23 | 392 | |
| Debora Beldì | 89 | 136 | 129 | 113 | 22 | 388 | |
| Yukio Akagi | 136 | 212 | 110 | 143 | 27 | 386 | |
| Heming Lu | 173 | 149 | 104 | 279 | 23 | 398 | |
| Helena Sjödin | 89 | 106 | 180 | 201 | 12 | 377 | |
| Wei Hu | 72 | 140 | 81 | 188 | 18 | 361 | |
| Markus K. A. Herrmann | 171 | 117 | 216 | 46 | 18 | 384 | |
| A. Millà | 148 | 132 | 181 | 127 | 15 | 362 | |
| Danita Kannarunimit | 146 | 182 | 145 | 292 | 27 | 416 | |
| Oyeon Cho | 105 | 96 | 198 | 42 | 27 | 366 |
All Works
Loading papers...